TBPH Overview

Key Data

  • Open $14.08
  • Day Range 13.73 - 14.28
  • 52 Week Range 12.62 - 22.74
  • Market Cap $1.03B
  • Shares Outstanding 73.47M
  • Public Float 54.32M
  • Beta 1.01
  • Rev. per Employee $200.16K
  • P/E Ratio N/A
  • EPS -$4.11
  • Yield N/A
  • Dividend N/A
  • Ex-Dividend Date N/A
  • Short Interest 2.71M 07/30/21
  • % of Float Shorted 4.99%
  • Average Volume 424.98K

Performance

5 Day
  • 10.70%
1 Month
  • 3.66%
3 Month
  • -15.05%
YTD
  • -20.26%
1 Year
  • -21.01%

Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 9 Full Ratings

Recent News

  • MarketWatch
  • Dow Jones

Theravance Biopharma stock price target cut to $23 from $27 at J.P. Morgan

Aug. 24, 2021 at 8:04 a.m. ET by Tomi Kilgore

Theravance Bio stock falls more than 20% after drug trial disappoints

Aug. 23, 2021 at 4:51 p.m. ET by Claudia Assis

Theravance Biopharma Shares Drop 7% After Public Offering Prices

Jun. 25, 2021 at 12:44 p.m. ET

Theravance Biopharma Prices Offering of 6.7M Shares at $15 a Share

Jun. 25, 2021 at 6:49 a.m. ET
Barron's

Theravance Stock Drops on Covid-19 Therapy Disappointment

Jun. 21, 2021 at 8:16 a.m. ET by Barron's

Theravance Biopharma's Study of Covid-19-Related Lung Injury Drug Didn't Meet Primary Endpoint

Jun. 21, 2021 at 6:28 a.m. ET

Theravance Biopharma initiated at overweight with $29 price target at JPMorgan

Jul. 7, 2020 at 8:29 a.m. ET by Tonya Garcia

Drug maker stocks rally after AbbVie's deal to buy Allergan for 45% premium

Jun. 25, 2019 at 7:42 a.m. ET by Tomi Kilgore

Theravance Biopharma downgraded to underperform from neutral at RW Baird

Oct. 12, 2016 at 7:02 a.m. ET by Tomi Kilgore

Theravance Biopharma downgraded to underperform from neutral at BofA Merrill Lynch

Aug. 3, 2016 at 11:44 a.m. ET by Tomi Kilgore

Investors shouldn’t fear this pullback, they should embrace it

Aug. 3, 2016 at 11:11 a.m. ET by Kevin Marder

Theravance Biopharma started at outperform with $26 stock price target at Leerink Partners

May. 12, 2016 at 7:28 a.m. ET by Tomi Kilgore
Barron's

Eight Undervalued Key Antibiotics Players

Feb. 25, 2015 at 11:00 a.m. ET
  • Other News
  • Press Releases

Leerink Partners Thinks Theravance Biopharma’s Stock is Going to Recover

Aug. 24, 2021 at 7:45 a.m. ET on TipRanks.com

Evercore ISI Remains a Buy on Theravance Biopharma (TBPH)

Aug. 5, 2021 at 3:50 a.m. ET on TipRanks.com

Bausch's (BHC) Q2 Earnings Beat Estimates, Revenues Miss

Aug. 4, 2021 at 11:01 a.m. ET on Zacks.com

Pacira's (PCRX) Q2 Earnings Beat Estimates, Revenues Rise Y/Y

Aug. 4, 2021 at 10:38 a.m. ET on Zacks.com

Theravance Biopharma, inc (TBPH) Q2 2021 Earnings Call Transcript

Aug. 4, 2021 at 10:01 a.m. ET on Motley Fool

Theravance's (TBPH) Q2 Earnings Beat, Pipeline On Track

Aug. 4, 2021 at 9:44 a.m. ET on Zacks.com

Theravance Biopharma (TBPH) Receives a Buy from Leerink Partners

Aug. 4, 2021 at 8:27 a.m. ET on TipRanks.com

Needham Thinks Theravance Biopharma’s Stock is Going to Recover

Aug. 4, 2021 at 6:47 a.m. ET on TipRanks.com

Analysts Offer Insights on Healthcare Companies: Alphatec Holdings (ATEC), Pacira Pharmaceuticals (PCRX) and Theravance Biopharma (TBPH)

Aug. 4, 2021 at 6:15 a.m. ET on TipRanks.com

Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates

Aug. 3, 2021 at 5:25 p.m. ET on Zacks.com

3 “Strong Buy” Stocks Trading at Steep Discounts

Aug. 2, 2021 at 10:26 a.m. ET on TipRanks.com

Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Jul. 27, 2021 at 3:03 p.m. ET on Zacks.com

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Jun. 25, 2021 at 7:24 a.m. ET on InvestorPlace.com

Theravance (TBPH) COVID-19 Therapy Fails in Mid-Stage Study

Jun. 22, 2021 at 9:51 a.m. ET on Zacks.com

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Jun. 21, 2021 at 7:25 a.m. ET on InvestorPlace.com

Theravance Bio (TBPH) Down 13% Since Last Earnings Report: Can It Rebound?

Jun. 3, 2021 at 11:31 a.m. ET on Zacks.com

Theravance (TBPH) Q1 Earnings Lag Estimates, Pipeline on Track

May. 5, 2021 at 10:45 a.m. ET on Zacks.com

Theravance Biopharma (TBPH) Receives a Buy from Leerink Partners

May. 5, 2021 at 8:25 a.m. ET on SmarterAnalyst

Theravance Biopharma Inc (TBPH) Q1 2021 Earnings Call Transcript

May. 5, 2021 at 12:01 a.m. ET on Motley Fool

Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates

May. 4, 2021 at 5:20 p.m. ET on Zacks.com

Theravance Biopharma Inc.

Theravance Biopharma, Inc. operates as a biopharmaceutical company. It focuses on the discovery, research, development, and commercialization of organ-selective medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

Competitors

Name Chg % Market Cap
Collegium Pharmaceutical Inc. 2.88% $717.34M
Cumberland Pharmaceuticals Inc. -4.82% $43.3M
Corcept Therapeutics Inc. 1.46% $2.39B
Competitor Data Provided ByCapital Cube Logo